Global Cheminformatics Market Report to 2027 – Featuring Agilent Technologies, Bio-Rad Laboratories, PerkinElmer and Accelrys Software Among Others – Yahoo Finance
Dublin, Nov. 09, 2022 (GLOBE NEWSWIRE) — The “Global Cheminformatics Market by Application, End-user, Company, and Region: Competition Forecast and Opportunities to 2027” report has been added to ResearchAndMarkets.com’s offering.
The Global cheminformatics market is anticipated to observe an impressive growth in the forecast period. The major factors like increasing awareness of personalized medicine combined with unsustainable liability of chronic disease are propelling the growth of global cheminformatics market.
Moreover, due to the awareness of personalized drugs among people, a sudden increase in usage of stratified medicines has made a positive influence on the cheminformatics market.
Furthermore, the other factors which impel the growth of the market are increasing investments in research and development to validate potential drug candidates and effectively operate data generated in the course of molecular and atomic reactions. The advancements in the new drug discovery process is a contributing factor for the growth of the market as it helps to design targeted drugs which help to advance public health and care.
Increasing Awareness Pertaining to Personalized Medicines
The increased awareness regarding the personalized medicines and surge in chronic diseases is driving the Cheminformatics market growth, globally. Nowadays, people are aware of these precision drugs due to various initiatives such as The European Cancer Patient Coalition (ECPC) launched a campaign in 2018 to spread awareness regarding the personalized drugs and its function. Therefore, due to the awareness among people, demand for customized medicine is forecast to witness a positive impact on the Cheminformatics market.
Design and Developments
Cheminformatics primarily deals with the new drug discovery which helps to treat various diseases without any side effects, propelling the growth of global cheminformatics market. When these drugs are being synthesized, a vast amount of data is produced, which results in designing of a new drug molecule. Also, the leading market players are combining innovative information storage and retrieval technologies in cheminformatics.
In addition, advancements in drug developments process have driven the growth of the market as various modern drug development techniques are being used instead of traditional drug discovery method. For instance, In-silico techniques are being used instead of traditional animal testing models as this technique helps to forecast the toxicity and evaluate the risk linked to it. Therefore, these technological advancements and developments will bolster the growth of cheminformatics market globally in upcoming years.
Increasing Investments to Boost Cheminformatics Market
Various investments in research and development (R&D) projects are done which also fuels the demand for cheminformatics to validate potential drug candidates and effectively operate data generated during molecular reactions. For instance, in 2020, research and development expenditure on pharmaceutical companies in the Unites States was USD 91.1 billion.
Market Segmentation
The global cheminformatics market is segmented into application, end-user, company, and region. Based on application, the market is divided into chemical analysis, drug discovery and validation, virtual screening, and others. Based on end-user, the market is divided into chemical & pharmaceutical companies, academic & research institutions, and others.
In terms of country, the United States is expected to be a lucrative market in the forecast period as the government is investing in R&D initiatives, and technological expansions in the country.
Market Players
Agilent Technologies Inc., Bio-Rad Laboratories Inc., PerkinElmer NC., Accelrys Software Inc., Chemical Computing Group, Inc., Certara, L.P., Advanced Chemistry Development, Inc. (ACD/Labs), BioSolveIT GmbH, BIOVIA (Dassault Systemes), ChemAxon Inc., Eurofins CEREP SA (Eurofins Panlabs Inc.), Jubilant Biosys Inc., Molecular Discovery Ltd., OpenEye Scientific Software Inc., Schrodinger Inc are the key players operating in the cheminformatics market.
Key Topics Covered:
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Cheminformatics Market
5. Voice of Customer
6. Global Cheminformatics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application (Chemical Analysis, Drug Discovery and Validation, Virtual Screening, Others)
6.2.2. By End-user (Chemical & Pharmaceutical Companies, Academic & Research Institutions, Others)
6.2.3. By Company (2021)
6.2.4. By Region
6.3. Product Market Map
7. North America Cheminformatics Market Outlook
8. Europe Cheminformatics Market Outlook
9. Asia-Pacific Cheminformatics Market Outlook
10. South America Cheminformatics Market Outlook
11. Middle East and Africa Cheminformatics Market Outlook
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Agilent Technologies Inc.
14.2. Bio-Rad Laboratories Inc.
14.3. PerkinElmer, Inc.
14.4. Accelrys Software Inc.
14.5. Chemical Computing Group, Inc.
14.6. Certara, L.P.
14.7. Advanced Chemistry Development, Inc. (ACD/Labs)
14.8. BioSolveIT GmbH
14.9. BIOVIA (Dassault Systemes)
14.10. ChemAxon Inc.
14.11. Eurofins CEREP SA (Eurofins Panlabs Inc.)
14.12. Jubilant Biosys Inc.
14.13. Molecular Discovery Ltd.
14.14. OpenEye Scientific Software Inc.
14.15. Schrodinger Inc.
15. Strategic Recommendations
For more information about this report visit https://www.researchandmarkets.com/r/yzfm67
PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes immunodiagnostics, reproductive health, and applied genomics, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
While Bio-Rad Laboratories, Inc. ( NYSE:BIO ) shareholders are probably generally happy, the stock hasn't had…
Shares of solid-state electric battery-maker QuantumScape (NYSE: QS) were in freefall today, down 14% as of 3:21 p.m EST. The company reported third-quarter earnings at the end of October, but today's move was likely caused by a big analyst downgrade, sending the stock even lower than many other EV stocks, which also generally had a bad day today. This morning, Morgan Stanley analyst Adam Jonas issued a note on QuantumScape, downgrading his rating to the equivalent of a "sell," while lowering his price target on the stock from $12 to just $4.
Electric vehicles have gone from a backwater industry to a full-blown revolution over the last few years. Spurred on by the huge growth of Tesla, companies have committed to investing tons of money into the fast-growing sector of the economy. Here's one electric vehicle (EV) stock to buy right now, and two that will likely be poor investments going forward.
Shares of Amazon (NASDAQ: AMZN) took another step down today, even though there was no company-specific news about the tech giant. Amazon stock finished the day down 4.3%, while the Nasdaq lost 2.5%. While Amazon doesn't have direct exposure to the layoffs at the Facebook parent or the collapse in the crypto market, it arguably has more exposure to consumer and business spending than any other company.
Vermilion Energy Inc. ("Vermilion", "We", "Our", "Us" or the "Company") (TSX: VET) (NYSE: VET) is pleased to report operating and condensed financial results for the three and nine months ended September 30, 2022.
Yahoo Finance reporter Pras Subramanian explains how Tesla CEO Elon Musk's decision to sell nearly $4 billion worth of company shares is affecting the stock.
Here is the full text of a letter to Meta Platforms Inc. (Nasdaq:META) employees from CEO Mark Zuckerberg that was posted on Wednesday
In this article, we will discuss 15 stocks that will double in 2023. If you are short on time, you can skip our discussion and go straight to 5 Stocks That Will Double In 2023. We are almost through the nerve-racking year that 2022 was for equities. Inflation reached record highs, interest rates followed suit, […]
Yahoo Finance media reporter Allie Canal outlines Disney's latest earnings report and which revenue streams fell short on expectations.
Dead cat bounce? This legend certainly thinks so.
As cryptocurrency prices began to stabilize, fresh drama derailed the sense of relief that was finally settling into the crypto market this year. Sam Bankman-Fried, who emerged this summer as the savior of crypto firms on the verge of bankruptcy, agreed within 24 hours to sell his empire to his great rival Changpeng Zhao. This empire is made up of the FTX.com exchange, two of whose ambassadors are sports stars Stephen Curry and Tom Brady.
Apparel maker Hanesbrands (NYSE: HBI) probably wishes it had stayed warm and cozy in the underwear drawer on Wednesday. The company reported third-quarter results that not only missed on the top and bottom lines, but also came up short with guidance. Investors punished the company for these transgressions by trading its stock down nearly 9% on the day.
Crypto exchange Binance said it would walk away from an initial offer to acquire its competitor FTX after a review of the company’s finances.
In this article, we discuss the top 10 energy stock picks of Goldman Sachs. If you want to see more stocks in this selection, check out Goldman Sachs Energy Stocks: Top 5 Stock Picks. Jan Hatzius, Goldman Sachs’ chief economist, noted that there is a “very plausible” scenario where the US economy can steer clear […]
Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 75% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Synthetic-biology company Amyris (NASDAQ: AMRS) had an absolutely awful day on the stock exchange Wednesday, due to an earnings report that fell well short of expectations. After market hours on Tuesday, Amyris divulged its third-quarter results. Alas, the total fell far short of the average analyst estimate of just under $112 million.
In this article, we discuss the top 10 growth stock picks of Warren Buffett. If you want to see more stocks in this selection, check out Growth Stock Portfolio: 5 Stock Picks By Warren Buffett. Investors for the past few months have been piling into companies with resilient growth prospects over cheaper value stocks. This […]
In this article, we discuss Charlie Munger’s stock portfolio and his 5 biggest stock positions. You can skip our introductory talk on Charlie Munger and read Charlie Munger Stock Portfolio: 2 Biggest Positions. Charlie Munger, the 98-year-old billionaire investor and a partner of Warren Buffett, bought the Daily Journal in late 1970s through the New […]
(Bloomberg) — Amazon.com Inc. is the world’s first public company to lose a trillion dollars in market value as a combination of rising inflation, tightening monetary policies and disappointing earnings updates triggered a historic selloff in the stock this year. Most Read from BloombergSam Bankman-Fried’s $16 Billion Fortune Is Eviscerated in DaysMeta to Cut 11,000 Jobs; Zuckerberg Says ‘I Got This Wrong’Hochul Wins NY Governor Race as GOP’s Zeldin Refuses to ConcedeBinance Backs Out of FTX Re